BTA's credibility is on the line here, they have not managed GSK's 'best endeavours' in a professional and business like manner and have been poor decision makers.
The market must have serious concerns about current BTA management taking Lani forward for fear of a repetition of the GSK experience or something similar derailing Lani.
I believe that a buyout is likely, orchestrated by major holders. Time is up for current management
BTA Price at posting:
$1.22 Sentiment: Hold Disclosure: Held
